The Mission of the Yale Center for Molecular Discovery (YCMD) is to blend innovative research capabilities and practical experience to develop a nimble means to accelerate basic scientific concepts into innovative applications. YCMD works with investigators with breakthrough ideas and works with them to accelerate and broaden the potential for new grants, manuscripts and future partnerships. Our mission is accomplished using a mix of internal laboratory expertise with consultative services to provide customized solutions for the unique challenges of each project. YCMD seeks to synergize existing technologies and expertise in a manner that expands the quality and breadth of services to investigators in a cost-effective manner. Prominent services include the development of robust assays for high content and/or high-throughput screening. Complementing this, YCMD amassed the reagents and expertise to conduct screening campaigns with small molecule and/or siRNA libraries. These activities have been successfully utilized to facilitate the discovery and prosecution of new targets that are relevant to cancer. Recently, YCMDs impact increased by providing much-needed chemistry-based services, including ligand and structure based design, compound synthesis and analoging and natural product library generation. Beyond the discovery of novel targets and agents, YCMD works with Yale Cancer Center investigators to identify opportunities for synergistic combination of known antitumor agents. Each project is tailored to meet the specific needs of our customers. Key considerations for each project are the time, cost, and probability of meeting the investigator research goal. In partnership with a representative from each laboratory, we combine precise knowledge of the research field and specific handling considerations of experimental reagents. Barriers to new technology can be daunting, especially those involving sophisticated instrumentation;thus we streamline and direct the screening process for each project to maximize efficiency of all resources.

Public Health Relevance

The Yale Center for Molecular Discovery (YCMD) works with investigators with breakthrough ideas and works with them to accelerate and broaden the potential for new grants, manuscripts and future partnerships. YCMD's mission is accomplished using a mix of internal laboratory expertise with consultative services to provide customized solutions for the unique challenges of each project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-35
Application #
8755640
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
35
Fiscal Year
2014
Total Cost
$96,446
Indirect Cost
$38,521
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Ols, Michelle L; Cullen, Jaime L; Turqueti-Neves, Adriana et al. (2016) Dendritic Cells Regulate Extrafollicular Autoreactive B Cells via T Cells Expressing Fas and Fas Ligand. Immunity 45:1052-1065
Gale, Molly; Sayegh, Joyce; Cao, Jian et al. (2016) Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance. Oncotarget 7:39931-39944
Ducker, Gregory S; Chen, Li; Morscher, Raphael J et al. (2016) Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. Cell Metab 23:1140-53
Adams, Brian D; Wali, Vikram B; Cheng, Christopher J et al. (2016) miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Res 76:927-39
Santin, Alessandro D; Bellone, Stefania; Buza, Natalia et al. (2016) Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clin Cancer Res 22:5682-5687
de Haydu, Christopher; Black, Jonathan D; Schwab, Carlton L et al. (2016) An update on the current pharmacotherapy for endometrial cancer. Expert Opin Pharmacother 17:489-99
Hollander, Lindsay; Guo, Xiaojia; Velazquez, Heino et al. (2016) Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism. Cancer Res 76:3884-94
Zhao, Siming; Bellone, Stefania; Lopez, Salvatore et al. (2016) Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 113:12238-12243
Park, Sin-Aye; Lee, Jong Woo; Herbst, Roy S et al. (2016) GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer. PLoS One 11:e0153075
Stein, Stacey M; James, Edward S; Deng, Yanhong et al. (2016) Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 114:737-43

Showing the most recent 10 out of 275 publications